http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101010339-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate | 2005-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a2a4bc9a200a8eacaf4a7e88e4ddd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d7c601ea26f2604e0d740bf4998048c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dc91b9d3cae805086bfc4abf28233bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3005c991db7f2f8252f5cc496e13813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0084d940d4b6b9ccffd6d12a43e80956 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd76644c106f615132696449299664e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bf77df6d4ed335e11acbc4e14ed39af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21fd7fbb79f28d9512cc7fed659169f6 |
| publicationDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101010339-B |
| titleOfInvention | Human glucagon-like peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| abstract | The present invention provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators, which have biological activity similar to or superior to native GLP-1 peptides, and are therefore useful for the treatment or prophylaxis associated with GLP activity disease or condition is useful. Further, the present invention provides novel chemically modified peptides that not only stimulate insulin secretion in type II diabetic patients, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability towards proteolytic cleavage, making them ideal therapeutic candidates for oral or parenteral administration. The peptides of the invention exhibit desirable pharmacokinetic properties as well as desirable potency in an effector model of diabetes. |
| priorityDate | 2004-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.